Strs Ohio boosted its stake in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 9.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 54,500 shares of the specialty pharmaceutical company’s stock after buying an additional 4,800 shares during the quarter. Strs Ohio owned approximately 0.16% of Collegium Pharmaceutical worth $625,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. First Quadrant L P CA raised its holdings in Collegium Pharmaceutical by 87.2% in the 2nd quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock valued at $59,000 after acquiring an additional 2,089 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 1,299.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,495 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 7,888 shares during the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth $98,000. Paradigm Capital Management Inc. NY acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth $131,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth $116,000. 92.17% of the stock is currently owned by hedge funds and other institutional investors.
COLL has been the subject of a number of research analyst reports. William Blair restated a “buy” rating on shares of Collegium Pharmaceutical in a report on Tuesday, September 17th. SunTrust Banks upped their price target on shares of Collegium Pharmaceutical to $22.00 and gave the stock a “buy” rating in a research report on Friday. Jefferies Financial Group upped their price target on shares of Collegium Pharmaceutical from $26.00 to $36.00 in a research report on Thursday. BidaskClub raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $24.57.
Shares of COLL stock opened at $19.96 on Friday. The stock has a market capitalization of $459.95 million, a price-to-earnings ratio of -16.77 and a beta of 0.52. Collegium Pharmaceutical Inc has a one year low of $10.01 and a one year high of $19.99. The company’s 50-day simple moving average is $12.16 and its 200-day simple moving average is $12.08. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.20 and a current ratio of 1.25.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The firm had revenue of $72.94 million during the quarter, compared to analyst estimates of $74.32 million. During the same quarter in the previous year, the business posted ($0.50) EPS. Collegium Pharmaceutical’s revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, research analysts forecast that Collegium Pharmaceutical Inc will post -0.51 EPS for the current year.
In related news, Director David Hirsch sold 22,106 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total transaction of $257,534.90. Following the completion of the sale, the director now directly owns 64,223 shares in the company, valued at $748,197.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Joseph Ciaffoni sold 64,821 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the completion of the transaction, the chief executive officer now directly owns 242,276 shares of the company’s stock, valued at approximately $4,547,520.52. The disclosure for this sale can be found here. 8.08% of the stock is currently owned by company insiders.
Collegium Pharmaceutical Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Story: How does a dividend reinvestment plan work?
Receive News & Ratings for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
